CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
ongoing trials trial from www.clinicaltrials.gov

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance - Phase 2 - Not yet recruiting

  • Year: 2021
  • Date: April 1, 2021
  • Author: University of Pennsylvania|Children's Hospital of Philadelphia
Source

https://ClinicalTrials.gov/show/NCT04731272

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other

Participants

Cystic Fibrosis|Pancreatic Insufficiency|Abnormal Glucose Tolerance|Diabetes - 18 Years and older   (Adult, Older Adult)

Interventions

Drug: Dulaglutide 0.75Mg/0.5Ml Inj Pen

Outcome measures

Early-phase insulin secretion|Early-phase insulin secretion adjusted for glucose excursion|Glucose tolerance

Keywords: Adult; Child; Diabetes Mellitus; Gastrointestinal Diseases; Glucose Intolerance; Hypoglycemic Agents; Pancreatic Diseases; pharmacological_intervention; GLP-1 agonists; dulaglutide;